Format

Send to

Choose Destination
J Infect Dis. 2016 Dec 15;214(suppl 5):S500-S505.

Chikungunya Virus Vaccines: Viral Vector-Based Approaches.

Author information

1
Themis Bioscience, Vienna, Austria.
2
Viral Genomics and Vaccination Unit, CNRS UMR 3569, Institut Pasteur, Paris, France.

Abstract

In 2013, a major chikungunya virus (CHIKV) epidemic reached the Americas. In the past 2 years, >1.7 million people have been infected. In light of the current epidemic, with millions of people in North and South America at risk, efforts to rapidly develop effective vaccines have increased. Here, we focus on CHIKV vaccines that use viral-vector technologies. This group of vaccine candidates shares an ability to potently induce humoral and cellular immune responses by use of highly attenuated and safe vaccine backbones. So far, well-described vectors such as modified vaccinia virus Ankara, complex adenovirus, vesicular stomatitis virus, alphavirus-based chimeras, and measles vaccine Schwarz strain (MV/Schw) have been described as potential vaccines. We summarize here the recent data on these experimental vaccines, with a focus on the preclinical and clinical activities on the MV/Schw-based candidate, which is the first CHIKV-vectored vaccine that has completed a clinical trial.

KEYWORDS:

MVA; VSV; adenovirus vector; chikungunya virus; measles virus vector; vaccine; viral vectors

PMID:
27920181
DOI:
10.1093/infdis/jiw369
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center